” DT56a was effective against symptomatic vulvo-vaginal atrophy (vaginal dryness)…”

A Prospective Study of DT56a (Femarelle®) for the Treatment of Postmenopausal
Vaginal Atrophy

Published in: Journal of Endocrinological Investigation 2013;36(7):521-6.

Efficacy and safety of DT56a compared to hormone therapy in Greek post-menopausal women.

Labos G, Trakakis E, Pliatsika P, Augoulea A, Vaggopoulos V, Basios G, Simeonidis G, Creatsa M, Alexandrou A, Iliodromiti Z, Kassanos D, Lambrinoudaki I.


Hormone therapy (HT) is the treatment of choice for the alleviation of menopausal symptoms; concerns, however, about its concomitant long-term health risks have limited its use. DT56a is a unique enzymatic isolate of soybeans. The purpose of our study was to evaluate the efficacy and safety of DT56a, compared to HT, in symptomatic post-menopausal women.


DT56a decreased menopausal symptoms significantly and in the same degree as HT

For full abstract>